DeepMed Research

RUTGERS, THE STATE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer
Metastatic Breast Cancer
Advanced Breast Cancer
HER2/Neu-positive Breast Cancer

Interventions: Drug: Capecitabine
Drug: Lapatinib

First Posted Date: 2007-07-04

Last Posted Date: 2017-03-21

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 11

Registration Number: NCT00496366

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Rutgers Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States

Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon-beta 1b (Betaseron)

First Posted Date: 2007-05-02

Last Posted Date: 2015-05-07

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 24

Registration Number: NCT00468182

Locations: 🇺🇸
Rutgers-RWJMS, New Brunswick, New Jersey, United States

Correlation BIS Scores Mentally Retarded Patients

Completed

Conditions: Mental Retardation

Interventions: Device: BIS monitor

First Posted Date: 2007-05-02

Last Posted Date: 2016-11-01

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 90

Registration Number: NCT00468338

Locations: 🇺🇸
UMDNJ University Hospital, Newark, New Jersey, United States

Coping With Depression in Parkinson's Disease

Not Applicable

Completed

Conditions: Parkinson's Disease
Depression

Interventions: Behavioral: cognitive-behavioral therapy

First Posted Date: 2007-04-23

Last Posted Date: 2014-11-05

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 80

Registration Number: NCT00464464

Locations: 🇺🇸
Rutgers, Robert Wood Johnson Medical School, 675 Hoes Lane, Room D-317, Piscataway, New Jersey, United States

Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: imatinib mesylate

First Posted Date: 2006-05-09

Last Posted Date: 2023-03-29

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 49

Registration Number: NCT00323063

Locations: 🇺🇸
Saint Peter's University Hospital, New Brunswick, New Jersey, United States
🇺🇸
Cooper Hospital/University Medical Center, Camden, New Jersey, United States
🇺🇸
Rutgers Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States

and more 6 locations

Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: imatinib mesylate

First Posted Date: 2006-05-09

Last Posted Date: 2014-05-22

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 17

Registration Number: NCT00323362

Locations: 🇺🇸
Saint Peter's University Hospital, New Brunswick, New Jersey, United States
🇺🇸
Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Health-related Quality of Life Measure in Pediatric Lupus

Completed

Conditions: Systemic Lupus Erythematosus
Quality of Life

First Posted Date: 2006-01-20

Last Posted Date: 2016-04-11

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 31

Registration Number: NCT00280137

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
La Rabida Children's Hospital - The University of Chicago, Chicago, Illinois, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States

and more 8 locations

HRV Biofeedback in Fibromyalgia

Not Applicable

Completed

Conditions: Fibromyalgia Syndrome

Interventions: Behavioral: RSA Biofeedback
Behavioral: EEG Biofeedback Condition

First Posted Date: 2005-09-22

Last Posted Date: 2015-02-09

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 80

Registration Number: NCT00222274

Locations: 🇺🇸
UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Etoposide
Drug: Cyclophosphamide

First Posted Date: 2005-09-15

Last Posted Date: 2014-05-20

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 15

Registration Number: NCT00176605

Locations: 🇺🇸
UMDNJ/Robert Wood Johnson Medical School, Newark, New Jersey, United States
🇺🇸
Robert Wood Johnson University Hospital/CINJ at Hamilton, Hamilton, New Jersey, United States
🇺🇸
Morristown Memorial Hospital, Morristown, New Jersey, United States

and more 4 locations

Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Phase 2

Terminated

Conditions: Kidney Cancer

Interventions: Biological: therapeutic allogeneic lymphocytes

First Posted Date: 2005-09-15

Last Posted Date: 2014-01-06

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 3

Registration Number: NCT00176501

Locations: 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy